Meet us at the Targeted Radiopharmaceuticals Summit 2021
Minerva Imaging will be presenting at the 3rd Annual Targeted Radiopharmaceuticals Summit, 7-9 December in Berlin, Germany. Please join our co-founders Carsten H. Nielsen, CEO, and Andreas Kjaer, CSO, during the presentation about Minerva Imaging’s fully integrated solution for development of theranostics with a translational focus.
If you are interested in learning more about our services or set up a meeting during the congress, please feel free to contact co-founder and CEO, Carsten H. Nielsen or co-founder and CSO, Andreas Kjaer.
About Minerva Imaging
Minerva Imaging is a scientifically driven CRO focussed on targeted radionuclide therapy with the use of advanced oncology models and molecular imaging for translational cancer research and drug development.
With over 10 years of experience in targeted radionuclide therapy, we are experts in designing and performing preclinical targeted radionuclide therapy studies. We operate a facility with on-site radiochemistry and vivarium for small and large animals equipped with molecular imaging systems. We are licensed to work with relevant isotopes for targeted radionuclide therapy and diagnostics.
We engage with our clients to understand their scientific questions and discuss how our methods and capabilities can provide answers. Our competences build on more than two decades of research within oncology, targeted radionuclide therapy and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.